^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ethynylcytidine (TAS-106)

i
Other names: TAS-106, ECyD, SB 596168
Associations
Trials
Company:
Otsuka
Drug class:
RNA polymerase inhibitor
Associations
Trials
over2years
The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression. (PubMed, Front Oncol)
By harnessing the catalytic activity of UCK2, several cytotoxic ribonucleoside analogs, such as TAS-106 and RX-3117, have been developed for UCK2-mediated cancer chemotherapy. These findings suggest that UCK2 may serve as a potential therapeutic target for cancer treatment. In this mini-review, we introduced the genomic localization and protein structure of UCK2, described the role of UCK2 in tumor development, discussed the application of UCK2 in anti-tumor treatment, and proposed concurrent targeting of the catalytic and non-catalytic roles of UCK2 as a potential therapeutic strategy for cancer treatment.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
ethynylcytidine (TAS-106) • roducitabine (PCS3117)